Scholarlink

<p>Antimicrobial resistance poses significant challenges, particularly with <i>Stenotrophomonas maltophilia</i>, a bacterium intrinsically resistant to antibiotics. This resistance is primarily attributed to the production of L1 β-lactamase, a metallo β-lactamase belonging to subclass B3 of the Ambler class enzymes. Chromosomally encoded, L1 β-lactamase hydrolyzes a broad spectrum of β-lactam antibiotics, including carbapenems, which are often considered the last-resort treatment for bacterial infections. The neutralization of many β-lactam antibiotics by this enzyme severely limits treatment options, making infections increasingly difficult to manage. To address this, research into specific inhibitors of L1 β-lactamase is gaining momentum, with the potential to pave the way for novel therapeutic agents targeting this enzyme. This study employs high-throughput virtual screening of FDA-approved drugs using AutoDock Vina, selecting the top 20 compounds based on the lowest binding energy. These compounds are further evaluated through ADMET, PAINS, density functional theory, and molecular dynamics simulations for 500&#xa0;ns, followed by binding free energy examination using the MM/PBSA method. Through this in silico approach, two drug compounds, Dolutegravir (−&#xa0;8.6&#xa0;kcal/mol) and Lumacaftor (−&#xa0;9.1&#xa0;kcal/mol), are identified as potential inhibitors based on their binding energies. The complexes demonstrate stability throughout the 500&#xa0;ns simulation. Dolutegravir (−&#xa0;61.54&#xa0;kJ/mol) exhibits stronger interaction with the protein compared to Lumacaftor (−&#xa0;53.43&#xa0;kJ/mol). These screened inhibitors open up possibilities for the development of combination therapies. Repurposing drugs offers a strategic advantage, as these compounds have already passed clinical safety tests, potentially reducing the cost and time required to bring new treatments to market. </p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Repurposing of FDA-approved drugs as potential inhibitors of L1 β-lactamase in Stenotrophomonas maltophilia

  • 期刊论文

  • 发表日期：

    2025年5月9日

查看全文
  • K. H. Sreenithya,
  • Dhananjay Jade,
  • Shobana Sugumar

摘要

Antimicrobial resistance poses significant challenges, particularly with Stenotrophomonas maltophilia, a bacterium intrinsically resistant to antibiotics. This resistance is primarily attributed to the production of L1 β-lactamase, a metallo β-lactamase belonging to subclass B3 of the Ambler class enzymes. Chromosomally encoded, L1 β-lactamase hydrolyzes a broad spectrum of β-lactam antibiotics, including carbapenems, which are often considered the last-resort treatment for bacterial infections. The neutralization of many β-lactam antibiotics by this enzyme severely limits treatment options, making infections increasingly difficult to manage. To address this, research into specific inhibitors of L1 β-lactamase is gaining momentum, with the potential to pave the way for novel therapeutic agents targeting this enzyme. This study employs high-throughput virtual screening of FDA-approved drugs using AutoDock Vina, selecting the top 20 compounds based on the lowest binding energy. These compounds are further evaluated through ADMET, PAINS, density functional theory, and molecular dynamics simulations for 500 ns, followed by binding free energy examination using the MM/PBSA method. Through this in silico approach, two drug compounds, Dolutegravir (− 8.6 kcal/mol) and Lumacaftor (− 9.1 kcal/mol), are identified as potential inhibitors based on their binding energies. The complexes demonstrate stability throughout the 500 ns simulation. Dolutegravir (− 61.54 kJ/mol) exhibits stronger interaction with the protein compared to Lumacaftor (− 53.43 kJ/mol). These screened inhibitors open up possibilities for the development of combination therapies. Repurposing drugs offers a strategic advantage, as these compounds have already passed clinical safety tests, potentially reducing the cost and time required to bring new treatments to market.

Graphical abstract